Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × INDUSTRY × Exenatide × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

pembrolizumab 206 Carboplatin 145 Injections 108 Paclitaxel 103 Cisplatin 102 Gemcitabine 97 Bevacizumab 97 Docetaxel 70 Pemetrexed 69 Cyclophosphamide 51 Capecitabine 47 Fulvestrant 45 Fluorouracil 45 Oxaliplatin 44 Nivolumab 42 Cetuximab 42 130-nm albumin-bound paclitaxel 41 atezolizumab 37 Dexamethasone 37 Rituximab 35 venetoclax 34 fludarabine 34 Leucovorin 33 toripalimab 32 Lenalidomide 32 enzalutamide 30 durvalumab 29 Drug Therapy 29 Prednisone 27 Azacitidine 27

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05663515 2026-02-12

EXCEED

AstraZeneca

24,000 enrolled

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡